LAMIVUDINE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C8H11N3O3S
Molecular Weight	229.2576
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

c1cn([C@]2([H])CS[C@]([H])(CO)O2)c(nc1=N)O

InChI

InChIKey=JTEGQNOMFQHVDC-NKWVEPMBSA-N

InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C8H11N3O3S
Molecular Weight	229.2576
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://pharmaffiliates.com/%C2%B1-trans-lamivudine/lamivudine-impurity-b-impurity/62787 | https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020564s035,020596s034lbl.pdf | https://newdrugapprovals.org/2016/03/18/lamivudine/http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020564s035,020596s034lbl.pdf
Curator's Comment:: Description was created based on several sources, including: http://www.drugbank.ca/drugs/DB00709 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2df7349c-f5d7-47b5-d29b-1b6b31985591

Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV). Intracellularly, lamivudine is phosphorylated to its active 5′-triphosphate metabolite, lamivudine triphosphate (3TC-TP). The principal mode of action of 3TC-TP is inhibition of HIV-1 reverse transcriptase (RT) via DNA chain termination after incorporation of the nucleotide analogue. The most common reported adverse reactions in adults are headache, nausea, malaise and fatigue. No data are available regarding interactions with other drugs that have renal clearance mechanisms similar to that of lamivudine.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Human immunodeficiency virus type 1 reverse transcriptase 45 Target ID: CHEMBL247 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020564s035,020596s034lbl.pdf	Inhibitor 7728		2.0 nM [IC50]
DNA polymerase/reverse transcriptase 9 Target ID: CHEMBL2362994 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021003s015,021004s015lbl.pdf	Inhibitor 7728		3.3 µM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Unknown 2502
HIV-1 infection 140 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020564s035,020596s034lbl.pdf	Primary	Approved 8043	EPIVIR Approved Use EPIVIR is a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. Launch Date 1.10108161E12
Chronic hepatitis B 15 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021003s015,021004s015lbl.pdf	Primary	Approved 8043	EPIVIR Approved Use EPIVIR-HBV is a nucleoside analogue reverse transcriptase inhibitor indicated for the treatment of chronic hepatitis B virus infection associated with evidence of hepatitis B viral replication and active liver inflammation Launch Date 1.10108161E12

C_max

Value	Dose	Co-administered	Analyte	Population
3.3 μg/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29150845	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:		LAMIVUDINE blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1.4 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020564s039,020596s038lbl.pdf	150 mg 2 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered:		LAMIVUDINE unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
12.4 μg × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29150845	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:		LAMIVUDINE blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
5.53 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020564s039,020596s038lbl.pdf	150 mg 2 times / day multiple, oral dose: 150 mg route of administration: Oral experiment type: MULTIPLE co-administered:		LAMIVUDINE unknown	Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
13.9 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/29150845	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:		LAMIVUDINE blood	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
100 mg 1 times / day multiple, oral Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10681323/	unhealthy, 14.6 n = 12 Health Status: unhealthy Condition: Chronic hepatitis B Age Group: 14.6 Sex: M+F Population Size: 12 Sources: https://pubmed.ncbi.nlm.nih.gov/10681323/	Other AEs: Malaise and fatigue, Ear, nose and throat infection... Other AEs: Malaise and fatigue (25%) Ear, nose and throat infection (17%) Cough (8%) Headache (17%) Nausea and vomiting (8%) Ear, nose and throat infection (8%) Sources: https://pubmed.ncbi.nlm.nih.gov/10681323/
10 mg/kg 2 times / day multiple, oral Highest studied dose Dose: 10 mg/kg, 2 times / day Route: oral Route: multiple Dose: 10 mg/kg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/7751691/	unhealthy, 37 years (range: 23-63 years) n = 14 Health Status: unhealthy Condition: HIV infection Age Group: 37 years (range: 23-63 years) Population Size: 14 Sources: https://pubmed.ncbi.nlm.nih.gov/7751691/	Other AEs: Coughing, Diarrhea... Other AEs: Coughing (6 patients) Diarrhea (9 patients) Abdominal discomfort (2 patients) Nausea and vomiting (1 patient) Malaise and fatigue (6 patients) Headache (6 patients) Disorder sleep (4 patients) Cognitive disorders (2 patients) Oral ulceration (2 patients) Oral lesion (2 patients) Muscle pain (3 patients) Arthralgia (1 patient) Temperature regulation disorder (2 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/7751691/
4 mg/kg 2 times / day multiple, oral Highest studied dose Dose: 4 mg/kg, 2 times / day Route: oral Route: multiple Dose: 4 mg/kg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/10681323/	unhealthy, 7.6 n = 11 Health Status: unhealthy Condition: Chronic hepatitis B Age Group: 7.6 Sex: M+F Population Size: 11 Sources: https://pubmed.ncbi.nlm.nih.gov/10681323/	Other AEs: Malaise and fatigue, Cough... Other AEs: Malaise and fatigue (27%) Cough (27%) Temperature regulation disorder NOS (27%) Nausea and vomiting (9%) Ear, nose and throat infection (18%) Ear disorder (9%) Pharyngitis (18%) Sources: https://pubmed.ncbi.nlm.nih.gov/10681323/
150 mg 1 times / day multiple, oral Recommended Dose: 150 mg, 1 times / day Route: oral Route: multiple Dose: 150 mg, 1 times / day Co-administed with:: zidovudine(200 mg; 3/day) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf	unhealthy n = 251 Health Status: unhealthy Condition: HIV-1 infection Population Size: 251 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf	Other AEs: Headache, Malaise and fatigue... Other AEs: Headache (35%) Malaise and fatigue (27%) Chills & fever (10%) Nausea (33%) Diarrhea (18%) Nausea and vomiting (13%) Decreased appetite (10%) Abdominal pain (9%) Abdominal cramps (6%) Dyspepsia (5%) Neuropathy (12%) Insomnia disorder (11%) Dizziness (10%) Depressive disorders (9%) Nasal disorders NEC (20%) Cough (18%) Skin rash (9%) Musculoskeletal pain (12%) Myalgia (8%) Arthralgia (5%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020564s37_020596s036lbl.pdf

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1467	inhibitor 1604	inhibitor 1702

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OATP1B1 733 OATP1B3 657 MATE2 251 OCT3 140 BCRP 643 P-gp 1330 OCT1 480 OCT2 594	MATE1 127 MATE2 91 OCT1 302 OCT2 316 P-gp 1400 BCRP 515 CYP 236

Drug as perpetrator

Target	Modality	Activity
CYP2C9 1648	inhibitor 3045 Sources: https://www.ema.europa.eu/en/documents/product-information/dovato-epar-product-information_en.pdf#page=21 Page: 21.0	no
CYP2D6 1738	inhibitor 3045 Sources: https://www.ema.europa.eu/en/documents/product-information/dovato-epar-product-information_en.pdf#page=21 Page: 21.0	no
CYP3A4 1772	inhibitor 3045 Sources: https://www.ema.europa.eu/en/documents/product-information/dovato-epar-product-information_en.pdf#page=21 Page: 21.0	no
MATE2 251	inhibitor 3045 Sources: https://www.pmda.go.jp/drugs/2020/P20200109001/340278000_30200AMX00001_I100_1.pdf#page=6 Page: 6.0	no
OATP1B1 748	inhibitor 3045 Sources: https://www.pmda.go.jp/drugs/2020/P20200109001/340278000_30200AMX00001_I100_1.pdf#page=6 Page: 6.0	no
OATP1B3 666	inhibitor 3045 Sources: https://www.pmda.go.jp/drugs/2020/P20200109001/340278000_30200AMX00001_I100_1.pdf#page=6 Page: 6.0	no
BCRP 713	inhibitor 3045 Sources: https://www.ema.europa.eu/en/documents/product-information/dovato-epar-product-information_en.pdf#page=21 Page: 21.0	weak to no
OCT3 140	inhibitor 3045 Sources: https://www.ema.europa.eu/en/documents/product-information/dovato-epar-product-information_en.pdf#page=21 Page: 21.0	weak to no
P-gp 1514	inhibitor 3045 Sources: https://www.ema.europa.eu/en/documents/product-information/dovato-epar-product-information_en.pdf#page=21 Page: 21.0	weak to no
OCT1 495	inhibitor 3045 Sources: https://www.pmda.go.jp/drugs/2020/P20200109001/340278000_30200AMX00001_I100_1.pdf#page=6 Page: 6.0	yes
OCT2 595	inhibitor 3045 Sources: https://www.pmda.go.jp/drugs/2020/P20200109001/340278000_30200AMX00001_I100_1.pdf#page=6 Page: 6.0	yes

Drug as victim

Target	Modality	Activity
CYP 236	substrate 3113 Sources: https://www.ema.europa.eu/en/documents/product-information/dovato-epar-product-information_en.pdf#page=21 Page: 21.0	not signifiicant
BCRP 515	substrate 3113 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020564s039,020596s038lbl.pdf#page=19 Page: 19.0	yes
MATE1 127	substrate 3113 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020564s039,020596s038lbl.pdf#page=19 Page: 19.0	yes
MATE2 91	substrate 3113 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020564s039,020596s038lbl.pdf#page=19 Page: 19.0	yes
OCT1 302	substrate 3113 Sources: https://www.ema.europa.eu/en/documents/product-information/dovato-epar-product-information_en.pdf#page=6 Page: 6.0	yes
OCT2 316	substrate 3113 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020564s039,020596s038lbl.pdf#page=19 Page: 19.0	yes
P-gp 1400	substrate 3113 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020564s039,020596s038lbl.pdf#page=19 Page: 19.0	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:63577	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:63577
ChemicalBook	CB1290608	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1290608
MolPort	MolPort-002-507-347	https://www.molport.com/shop/molecule-link/MolPort-002-507-347
Selleck Chemicals	Lamivudine(Epivir)	http://www.selleckchem.com/products/Lamivudine(Epivir).html
ZINC	ZINC000000012346	http://zinc15.docking.org/substances/ZINC000000012346
eMolecules	1987423	https://www.emolecules.com/cgi-bin/more?vid=1987423
eMolecules	2726078	https://www.emolecules.com/cgi-bin/more?vid=2726078
eMolecules	31588897	https://www.emolecules.com/cgi-bin/more?vid=31588897

PubMed

Title	Date	PubMed
A novel genotype encoding a single amino acid insertion and five other substitutions between residues 64 and 74 of the HIV-1 reverse transcriptase confers high-level cross-resistance to nucleoside reverse transcriptase inhibitors. Abacavir CNA2007 International Study Group.	1999 Oct 1	10843527
Antiviral combination therapy for lamivudine-resistant hepatitis B reinfection after liver transplantation.	2000	11112032
Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis.	2000 Aug	10952249
Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins.	2000 Dec	11145192
Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy.	2000 Dec 15	11141242
Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine.	2000 Feb	10707871
A randomized, comparative study of lamivudine plus stavudine, with indinavir or nelfinavir, in treatment-experienced HIV-infected patients.	2000 Jan 28	10708286
Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].	2000 Jul	10950391
Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.	2000 Jul	10889166
Management of hepatitis B in China.	2000 Jul	10861652
In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine.	2000 Jul	10858331
3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine.	2000 Jul 4	10877738
Presence of 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxath iole-2",2"-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patients.	2000 Jun 10	10875608
Steatosis-lactic acidosis syndrome associated with stavudine and lamivudine therapy.	2000 Jun 16	10894300
Synthesis and antiviral evaluation of some beta-L-2', 3'-dideoxy-5-chloropyrimidine nucleosides and pronucleotides.	2000 Mar	10771081
Severe hypertension and renal atrophy associated with indinavir.	2000 Mar	10722466
Selection and characterization of human immunodeficiency virus type 1 variants resistant to the (+) and (-) enantiomers of 2'-deoxy-3'-oxa-4'-thio-5-fluorocytidine.	2000 May	10770740
Selection of resistance-conferring mutations in HIV-1 by the nucleoside reverse transcriptase inhibitors (+/-)dOTC and (+/-)dOTFC.	2000 Nov	11227993
Correlation between intracellular pharmacological activation of nucleoside analogues and HIV suppression in vitro.	2000 Nov	11227992
An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy.	2000 Nov	11084061
Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine.	2000 Nov	11084057
Leucocytoclastic vasculitis and indinavir.	2000 Nov	11069541
Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.	2000 Oct	11003633
Sudden unexpected death as a consequence of indinavir-induced nephropathy. A case report.	2000 Sep	11110045
Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy.	2000 Sep	10960461
Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up.	2000 Sep 15	11003363
Antiviral beta-L-nucleosides specific for hepatitis B virus infection.	2001	11594678
Outcome of lamivudine resistant hepatitis B virus infection in liver transplant recipients in Singapore.	2001 Apr	11288740
Amino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistance profiles.	2001 Apr	11264389
Antiviral activity of beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine in woodchucks chronically infected with woodchuck hepatitis virus.	2001 Apr	11257017
Anti-HBV specific beta-L-2'-deoxynucleosides.	2001 Apr-Jul	11563077
Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples.	2001 Apr-Jul	11562951
Successful lamivudine therapy for post-chemotherapeutic fulminant hepatitis B in a hepatitis B virus carrier with non-Hodgkin's lymphoma: case report and review of the literature.	2001 Aug	11563596
Prenatal AZT or 3TC and mouse development of locomotor activity and hot-plate responding upon administration of the GABA(A) receptor agonist muscimol.	2001 Feb	11243490
Interferon therapy for flare-up of hepatitis B virus infection after emergence of lamivudine-induced YMDD motif mutant.	2001 Feb	11227671
Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis.	2001 Feb	11176135
A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.	2001 Feb	11172345
Antiviral L-nucleosides specific for hepatitis B virus infection.	2001 Jan	11120971
[Treatment of chronic viral hepatitis B with lamivudine].	2001 Jan 27	11225486
Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B.	2001 Jul	11480792
Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection.	2001 Jun	11451174
Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus.	2001 Jun	11353615
The real danger of lamivudine-resistant hepatitis B virus infection in the immunocompromised host.	2001 Mar	11244173
Efavirenz-induced acute eosinophilic hepatitis.	2001 May	11434632
4'-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro.	2001 May	11302824
Differential human immunodeficiency virus-suppressive activity of reverse transcription inhibitors in resting and activated peripheral blood lymphocytes: implications for therapy.	2001 May-Jun	11572234
Novel 5-vinyl pyrimidine nucleosides with potent anti-hepatitis B virus activity.	2001 Nov 19	11677126
Lamivudine treatment for hepatitis B reactivation in HBsAg carriers after organ transplantation: a 4-year experience.	2001 Sep	11595064
In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta-D-2,6-diaminopurine dioxolane and 2'-fluoro-5-methyl-beta-L-arabinofuranosyluracil.	2001 Sep	11502520
Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro.	2001 Sep	11448730

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Jun 25 21:02:24 UTC 2021` Edited by `admin` on `Fri Jun 25 21:02:24 UTC 2021`
Record UNII	2T8Q726O95
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LAMIVUDINE

Official Name

English

TEMIXYS COMPONENT LAMIVUDINE

Common Name

English

EPIVIR

Brand Name

English

LAMIVUDINE [EP MONOGRAPH]

Common Name

English

4-AMINO-1-((2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)PYRIMIDIN-2(1H)-ONE [WHO-IP]

Systematic Name

English

EMTRICITABINE IMPURITY C [WHO-IP]

Common Name

English

KIVEXA COMPONENT LAMIVUDINE

Common Name

English

LAMIVUDINUM [WHO-IP LATIN]

Common Name

English

GR-109714X

Code

English

COMBIVIR COMPONENT LAMIVUDINE

Common Name

English

LAMIVUDINE/ZIDOVUDINE TEVA COMPONENT LAMIVUDINE

Brand Name

English

TRIZIVIR COMPONENT LAMIVUDINE

Brand Name

English

VIROLAM

Common Name

English

LAMIVUDINE [WHO-IP]

Common Name

English

NSC-760061

Code

English

LAMIVUDINE [USP-RS]

Common Name

English

3TC

Code

English

TELURA COMPONENT OF LAMIVUDINE

Common Name

English

LAMIVUDINE [WHO-DD]

Common Name

English

LAMIVUDINE COMPONENT OF TRIUMEQ

Brand Name

English

LAMIVUDINE COMPONENT OF TRIZIVIR

Brand Name

English

LAMIVUDINE COMPONENT OF DUTREBIS

Brand Name

English

GR 109714X

Code

English

LAMIVUDINE COMPONENT OF DELSTRIGO

Brand Name

English

LAMIVUDINE COMPONENT OF COMBIVIR

Common Name

English

DELSTRIGO COMPONENT LAMIVUDINE

Brand Name

English

LAMIVUDINE COMPONENT OF TEMIXYS

Common Name

English

LAMIVUDINE [ORANGE BOOK]

Common Name

English

LAMIVUDINE TEVA

Brand Name

English

LAMIVUDINE [INN]

Common Name

English

ZEFFIX

Brand Name

English

LAMIVUDINE [HSDB]

Common Name

English

LAMIVUDINE [JAN]

Common Name

English

LAMIVUDINE TEVA PHARMA B.V.

Brand Name

English

(-)-1-((2R,5S)-2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)CYTOSINE

Systematic Name

English

LAMIVUDINE [EMA EPAR]

Common Name

English

LAMIVUDINE COMPONENT OF EPZICOM

Common Name

English

BCH 189, (-)-

Code

English

TRIUMEQ COMPONENT LAMIVUDINE

Brand Name

English

LAMIVUDINE COMPONENT OF LAMIVUDINE/ZIDOVUDINE TEVA

Brand Name

English

LAMIVUDINE [MART.]

Common Name

English

EPZICOM COMPONENT LAMIVUDINE

Common Name

English

LAMIVUDINE [USAN]

Common Name

English

LAMIVUDINE [VANDF]

Common Name

English

2(1H)-PYRIMIDINONE, 4-AMINO-1-(2-(HYDROXYMETHYL)-1,3-OXATHIOLAN-5-YL)-, (2R-CIS)-

Common Name

English

LAMIVUDINE [USP MONOGRAPH]

Common Name

English

LAMIVUDINE [EP]

Common Name

English

LAMIVUDINE [MI]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000175462